PURLs

An obesity remedy for diabetes

Author and Disclosure Information

 

References

WHAT’S NEW?: Evidence of efficacy has grown

This is the first RCT to evaluate biliopancreatic diversion and only the second to evaluate gastric bypass as strategies for controlling diabetes. Similar findings were demonstrated at 12 months in an RCT of 150 obese patients with diabetes in which intensive medical therapy was compared with either gastric bypass or sleeve gastrectomy,6 published concurrently with the Mingrone study. Like the Mingrone study, this study found that for select patients with diabetes, surgery may lead to better outcomes than medical management alone.

CAVEATS: Long-term effect is still uncertain

The long-term efficacy of surgery as a way to manage diabetes remains uncertain. Patients in this study were followed for just 2 years and the outcomes were metabolic measures rather than morbidity and mortality. A recent prospective observational study following patients for 6 years after gastric bypass found that the rate of remission for diabetes was 75% (95% confidence interval (CI), 63%-87%) at 2 years but dropped to 62% (95% CI, 49%-75%) at 6 years7

A larger study (N=4047) of longer duration—the Swedish Obese Subjects (SOS) cohort study —found a considerably larger drop: The diabetes remission rate for those who had surgery went from 72% at 2 years to 36% at 10-year follow-up, but that was still higher than the 10-year remission rate (13%) for the matched controls.4 It is still not clear exactly how long diabetic remission lasts after bariatric surgery or what effect a 10-year respite from the disease will have on the long-term morbidity and mortality of patients with diabetes.

Surgical risks. In small studies such as the one by Mingrone et al,1 it can be difficult to see the full extent of surgical complications. The much larger SOS study found low mortality rates (0.25%). But 13% of those who underwent bariatric surgery had postoperative complications (number needed to harm = 8), with 2.2% of patients requiring reoperation.4 Additionally, women who become pregnant after bariatric surgery are at increased risk for internal hernias or bowel obstruction during pregnancy.8

Furthermore, malabsorptive-type surgeries are known to cause nutritional deficiencies, leading to disorders including anemia and osteoporosis.6 Importantly, while women of childbearing-age who undergo bariatric surgery decrease their risk of developing gestational hypertension and gestational diabetes, they are more likely to have nutritional deficiencies during pregnancy and to have children with these deficiencies.8

CHALLENGES TO IMPLEMENTATION: The ideal candidate remains unclear

It is still not clear from this study which patients should be referred for bariatric surgery. Historically, BMI has been used as the main indication for bariatric surgery, but this and other, studies have found that remission of diabetes is independent of BMI and the amount of weight lost.9 A predictive 10-point Diabetes Surgery Score has recently been developed: It uses age, BMI, duration of diabetes, and C-peptide levels to predict the likelihood of diabetes remission after surgery.10 This scoring system has yet to be validated in non-Asian patients, and a threshold for recommending surgery has been not established. However, this tool indicates that younger patients with a shorter duration of diabetes (which was not a factor in the outcome of the Mingrone study) and no baseline use of insulin are most likely to benefit from surgery. Thus, these patients may be the ones we need to consider referring first.

Cost of surgery. Several studies have shown that bariatric surgery is cost-effective for the treatment of diabetes, and saves money after approximately 5 years.11,12 However, patients with diabetes and obesity may be uninsured or underinsured, and have high out-of-pocket costs. One challenge will be to ensure that surgery is a viable option for patients with financial constraints.

Acknowledgement

The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center for Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Pages

Copyright © 2013 The Family Physicians Inquiries Network. All rights reserved.

Recommended Reading

Insulin Degludec's Long Duration Sways FDA Panel
MDedge Family Medicine
Statins Sever the Diabetes and Coronary Disease Link
MDedge Family Medicine
In Type 1 Diabetes, Cardiac Measures Improved After Pancreas Transplant
MDedge Family Medicine
DPP-4 Inhibitors for Diabetes May Cut Cardiovascular Risk
MDedge Family Medicine
Statins' Diabetogenic Impact Influenced by Underlying Risks
MDedge Family Medicine
New Criteria for Gestational Diabetes Could Swamp Providers
MDedge Family Medicine
Primary care-based diabetes prevention programs reduce BMI
MDedge Family Medicine
Rate of visual impairment up 21%; diabetes is likely culprit
MDedge Family Medicine
Bariatric surgery cut vascular events in diabetes
MDedge Family Medicine
Diabetes confers 27% increase in breast cancer risk
MDedge Family Medicine